about
Cannabinoid-based drugs targeting CB1 and TRPV1, the sympathetic nervous system, and arthritisEmerging drugs for the treatment of anxietyPharmacological strategies for detoxification.Endocannabinoids and striatal function: implications for addiction-related behavioursMonoacylglycerol lipase inhibition blocks chronic stress-induced depressive-like behaviors via activation of mTOR signaling.Classification of Therapeutic and Experimental Drugs for Brown Adipose Tissue Activation: Potential Treatment Strategies for Diabetes and ObesityApplying a multitarget rational drug design strategy: the first set of modulators with potent and balanced activity toward dopamine D3 receptor and fatty acid amide hydrolase.Rimonabant improves metabolic parameters partially attributed to restoration of high voltage-activated Ca2+ channels in skeletal muscle in HFD-fed miceEstrogen receptor-{beta}-selective ligands alleviate high-fat diet- and ovariectomy-induced obesity in mice.Novel Electrophilic and Photoaffinity Covalent Probes for Mapping the Cannabinoid 1 Receptor Allosteric Site(s).Mitigation of post-traumatic stress symptoms by Cannabis resin: a review of the clinical and neurobiological evidence.Ghrelin-induced orexigenic effect in rats depends on the metabolic status and is counteracted by peripheral CB1 receptor antagonism.(4-(Bis(4-fluorophenyl)methyl)piperazin-1-yl)(cyclohexyl)methanone hydrochloride (LDK1229): a new cannabinoid CB1 receptor inverse agonist from the class of benzhydryl piperazine analogs.Diacylglycerol Lipase α Knockout Mice Demonstrate Metabolic and Behavioral Phenotypes Similar to Those of Cannabinoid Receptor 1 Knockout Mice.Rimonabant effects on anxiety induced by simulated public speaking in healthy humans: a preliminary report.Controlled downregulation of the cannabinoid CB1 receptor provides a promising approach for the treatment of obesity and obesity-derived type 2 diabetes.Cannabinoid Ligands and Alcohol Addiction: A Promising Therapeutic Tool or a Humbug?Activation of the sympathetic nervous system mediates hypophagic and anxiety-like effects of CB₁ receptor blockadeDabigatran - a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs.Effects of the cannabinoid-1 receptor antagonist rimonabant on psychiatric symptoms in overweight people with schizophrenia: a randomized, double-blind, pilot study.Immunoactive effects of cannabinoids: considerations for the therapeutic use of cannabinoid receptor agonists and antagonists.Marijuana Compounds: A Nonconventional Approach to Parkinson's Disease Therapy.The relationship between BMI and the prescription of anti-obesity medication according to social factors: a population cross sectional study.Endocannabinoid system dysfunction in mood and related disorders.Neuropsychiatric adverse effects of centrally acting antiobesity drugs.CB1 receptor antagonists: new discoveries leading to new perspectives.Review article: the reversibility of cirrhosis.Opposing local effects of endocannabinoids on the activity of noradrenergic neurons and release of noradrenaline: relevance for their role in depression and in the actions of CB(1) receptor antagonists.The endocannabinoid system in advanced liver cirrhosis: pathophysiological implication and future perspectives.Anandamide in primary sensory neurons: too much of a good thing?A novel live cell assay to measure diacylglycerol lipase α activityThe Potential Role of Cannabinoids in Modulating Serotonergic Signaling by Their Influence on Tryptophan MetabolismCannabinoid type 1 receptor antagonism ameliorates harmaline-induced essential tremor in rat.Constitutive Increases in Amygdalar Corticotropin-Releasing Factor and Fatty Acid Amide Hydrolase Drive an Anxious Phenotype.Differential effects of cannabinoid CB1 inverse agonists and antagonists on impulsivity in male Sprague Dawley rats: identification of a possibly clinically relevant vulnerability involving the serotonin 5HT1A receptor.Possible new targets for GPCR modulation: allosteric interactions, plasma membrane domains, intercellular transfer and epigenetic mechanisms.Weight reduction and maintenance with IQP-PV-101: a 12-week randomized controlled study with a 24-week open label period.Cannabinoid Modulation of the Stressed Hippocampus.New role of phenothiazine derivatives as peripherally acting CB1 receptor antagonizing anti-obesity agents.Cannabis, alcohol use, psychological distress, and decision-making style.
P2860
Q26783956-673F317F-4EBF-43AD-806F-5629E8B4B36BQ28083141-90456C90-1FF1-4F17-9859-90C7F7E573F6Q33582092-D01E879F-6499-41E6-BF1B-F4FCAB4861D4Q33583792-E450A461-9E74-411B-B763-14A85EF01653Q33620621-FA75C971-026D-42A7-B8D9-7EDC80A3712EQ33659194-2BF46D9C-89F0-4A86-896A-3EDE6586BE57Q33684510-340623C8-915B-4D1D-B17F-AA9C866221CDQ33718134-7F9A467F-BA51-4A7A-AE89-E49B863ECCC9Q34181302-716A3430-3777-4B4A-AE36-A409A85C233EQ34500324-5B32CCAA-94CA-4D58-9DF2-84C1558A8C57Q34639648-E41BF37F-90F9-4B80-964F-62E00A8DD043Q34658658-F22FCA0A-1DD3-41B6-8A63-271E432F3156Q34946743-EE887F2C-B2CC-4AD1-85FA-C30AF256BAC5Q35672654-25B9AC62-2287-4B84-9CAC-A456C79D8DA4Q35962896-5A09886D-4873-4E08-BA9A-0F9FD6215474Q36373581-6618C828-91DA-4A84-B91D-3D30935E9A5BQ36431393-004D3EF1-8B56-4E36-9B74-63C3D98429D6Q36712614-037DCB1D-9D59-48C5-8F02-77820EC6C1C7Q36841028-E06EE819-2084-4B9C-92CA-D96221CFDAF9Q37029513-566681E2-6A2D-4B3B-93E9-E0018BD7B3F0Q37244823-27735433-17DB-4C43-ADE0-41C1125DA6CFQ37512670-2CE4E3B3-1DC1-4B91-81DF-24FC1C3DAE75Q37557849-7F42C0A9-C840-4340-A3E4-8DB18F594643Q37932017-053C0951-97AA-4C6B-8C64-4CBF5F4BC4D4Q37939362-FFFD85C3-AFAF-44C1-A77E-3A0332F54C97Q37998561-F0B36AEE-8018-474B-A3A4-13A6546D0B0DQ38042443-B9E4F20C-BD1C-40CD-A41E-0B7E3DA5FA30Q38044652-FB4F620F-3BD0-4021-9AE8-B0DDA45B5AA2Q38124458-4AC575EC-C2E1-4DB1-AE60-E30677F0C133Q38185073-CE13C77A-FB1F-4000-B3EA-9A45FBCB70C5Q38783231-8D3BFFD8-3578-421B-91CF-8EDB364949DAQ38974424-EA439B6A-89CE-4E17-BC0F-F4138A822166Q39469519-0F217D0C-9DAF-4708-96E2-17CD053824FCQ45052909-CB9F7704-80BF-4EE9-B03A-B9EDF2D648D7Q45300313-78100985-27A6-41CD-A51C-83ECB4327AF7Q46065953-3B321E18-8BDF-4AF4-864D-0A383696995EQ46124082-E61F568C-0A48-480F-A6D7-FC39A0B9DF5DQ47661316-2AE5C275-A3CC-451F-A230-ED3BA1416A44Q47837489-527E9629-EA88-42AE-9441-80566C93D238Q47938383-8F4F08F7-92E0-4993-98F6-FF891378A960
P2860
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
The psychiatric side-effects of rimonabant.
@ast
The psychiatric side-effects of rimonabant.
@en
The psychiatric side-effects of rimonabant.
@nl
type
label
The psychiatric side-effects of rimonabant.
@ast
The psychiatric side-effects of rimonabant.
@en
The psychiatric side-effects of rimonabant.
@nl
prefLabel
The psychiatric side-effects of rimonabant.
@ast
The psychiatric side-effects of rimonabant.
@en
The psychiatric side-effects of rimonabant.
@nl
P2860
P1476
The psychiatric side-effects of rimonabant.
@en
P2093
Fabrício A Moreira
José Alexandre S Crippa
P2860
P304
P356
10.1590/S1516-44462009000200012
P577
2009-06-01T00:00:00Z